Service for specialized journalist

Grünenthal Press Releases 2017

Welcome to Grünenthal's Press Overview

23 May 2017

Cutting edge science in pain treatment in order to improve patients’ lives

EFIC-GRÜNENTHAL GRANT 2016 supports six young scientists in their advanced pain research projects

Brussels/Aachen, 23 May, 2017. The European Pain Federation EFIC® in cooperation with the pharmaceutical company Grünenthal announced that six young research scientists in the field of pain will be awarded an EFIC-GRÜNENTHAL Grant (E-G-G). This biennial grant, totalling € 200,000, supports up-and-coming pain scientists in translating their experimental project ideas into funded pain research projects.

More ...

10 May 2017

Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward

Aachen, Germany – Wednesday May 10, 2017. Grünenthal, a worldwide leader in Pain, announced today that it has opened a new Innovation Hub in the Greater Boston area. Through this Innovation Hub, Grünenthal aims to identify promising projects in pain, inflammation, orphan diseases, and devices & technologies from the large number of projects in late discovery and early development in the region. By building collaborative networks, in close partnership with institutions in the Boston area – from entrepreneurial scientists to successful spin-outs and start-ups – Grünenthal will drive these projects through research and development (R&D) in order to address the need for innovation.

More ...

09 May 2017

Mark Fladrich appointed new Chief Commercial Officer (CCO) at Grünenthal

Aachen, Germany, May 09, 2017. The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017.

More ...

02 May 2017

German Pain Specialist Grünenthal and 23andMe Explore the Genetics of Pain to Help Identify New Treatments for Patients

May 3, 2017 - Mountain View, Calif., and Aachen, Germany – Today 23andMe, Inc. and Grünenthal announced a joint study to better understand how genes influence pain. Together, they seek to enroll 20,000 participants from the U.S. The study will be one of the largest of its kind to combine data on genetics and response to pain, including a pain tolerance experiment. 23andMe is a leading personal genetics company, and the Grünenthal Group is an entrepreneurial, science-based German pharmaceutical company specializing in pain, gout and inflammation.

More ...

07 Apr 2017

The Grünenthal Group today announced the acquisition of the company Adhesys Medical to expand its pipeline of medical devices for its business with surgeons

Aachen, Germany, April 7, 2017. The Grünenthal Group today announced the acquisition of Adhesys Medical GmbH and its US-based affiliate Adhesys Medical Inc., a Medical Device Startup company focused on the development of adhesives used in surgery. Through this acquisition, Grünenthal has obtained the worldwide development and commercialization rights of an innovative pipeline of surgical sealants together with the underlying technology platform. The first innovative topical skin adhesive is expected to receive European-wide CE Marketing Certification within the next 12 months.

More ...

29 Mar 2017

Kuehne + Nagel becomes global transportation provider for the Grünenthal Group

Hamburg and Aachen / DE, 29. March 2017 - Logistics provider Kuehne + Nagel and pharmaceutical research company Grünenthal agree global partnership for land, air and seafreight. Kuehne + Nagel is supporting the Grünenthal Group with the reorganisation of the world-wide transportation network for highly sensitive pharmaceutical products.

More ...

12 Jan 2017

Grünenthal introduces Latin America’s most modern women’s health products plant

Santiago de Chile, Chile – January 12th, 2017: Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. The new facility will initially deliver high quality women’s health products to the Chilean market and – after the pending approval of the relevant authorities (INVIMA/ANVISA/COFEPRIS) – it will also provide products for other Latin American markets, including the biggest of the region: Brazil and Mexico. With this investment Grünenthal will improve the access of more than 168 million Latin American women to high quality health products.

More ...